In line with the in vitro results, ARNTL2 sensitized tumors to erlotinib as a single agent, highlighting ARNTL2 as a predictive biomarker for erlotinib response in pancreatic cancer. Here, BMAL2 is linked to familial pancreatic carcinoma.